Could Removing the Fallopian Tubes Prevent Ovarian Cancer?

Ovarian Cancer May Be Named for Where It Lands—not Where It Starts

For decades, ovarian cancer was assumed to begin in the ovaries. Pathology research has now shown that many high-grade serous cancers—the subtype responsible for most ovarian cancer deaths—appear to begin as tiny abnormal lesions near the fimbrial ends of the fallopian tubes.

These cells can escape from the tube, implant on the ovary and spread throughout the abdominal cavity. By the time the disease becomes visible on imaging or produces persistent symptoms, it may already be advanced.

This helps explain why ovarian cancer has been so difficult to detect early. There is currently no effective routine screening test for average-risk women, and neither transvaginal ultrasound nor CA-125 testing has been shown to detect the disease early enough to reduce mortality consistently.

A Potentially Powerful Prevention Opportunity

Opportunistic bilateral salpingectomy means removing both fallopian tubes during another medically appropriate surgery. The ovaries remain in place.

It may be considered when a woman who has completed childbearing is already undergoing:

• A hysterectomy with ovarian preservation
• Permanent contraception instead of conventional tubal ligation
• Another suitable pelvic operation
• In selected circumstances, another abdominal procedure where appropriately trained surgeons are available

This is not ordinarily a recommendation that an average-risk woman undergo a separate abdominal operation solely to remove her tubes. The preventive value is greatest when the procedure can be added safely to surgery that is already indicated.

What the 2026 Study Found

A 2026 British Columbia cohort study compared 40,527 women who underwent opportunistic bilateral salpingectomy with 45,296 women who had hysterectomy or tubal permanent contraception without complete removal of both tubes.

The researchers calculated an approximately 78% lower risk of serous ovarian cancer following salpingectomy. The ovarian cancers that did occur after tube removal were also substantially less likely to be high-grade serous cancers—the subtype most strongly associated with a fallopian-tube origin.

The findings strengthen an already considerable body of pathological, epidemiological and surgical evidence. A systematic review of 158 publications similarly concluded that salpingectomy was associated with an ovarian cancer risk reduction of approximately 80%.

Read the 2026 study in JAMA Network Open.

Why Preserving the Ovaries Matters

Removing the fallopian tubes is very different from removing the ovaries. The tubes transport eggs but do not provide the ovarian production of estradiol, progesterone and testosterone.

When both ovaries are removed before natural menopause, hormone production falls abruptly and surgical menopause begins. Depending on a woman’s age, health history and eligibility for hormone therapy, this may affect vasomotor symptoms, sexual function, bone density, cardiovascular risk, cognition and overall quality of life.

Salpingectomy aims to reduce cancer risk while leaving healthy ovaries and their hormone production intact. Existing evidence has not demonstrated a meaningful short-term adverse effect on ovarian function or the timing of menopause. However, the newest European consensus statement appropriately notes that very long-term evidence remains incomplete.

Important Limits Behind the “Nearly 80%” Headline

The finding is impressive, but it should be interpreted carefully.

• It is a relative risk reduction: The average woman’s lifetime ovarian cancer risk is already relatively low, so the absolute reduction is much smaller than 80 percentage points.
• It applies primarily to serous cancers: Salpingectomy cannot prevent every cancer that arises from the ovaries or peritoneum.
• The study was observational: It was not a randomized clinical trial, so unmeasured differences between the groups may have influenced the result.
• Few cancers occurred: This is encouraging, but it also creates statistical uncertainty around the exact size of the benefit.
• Follow-up differed: Median follow-up was approximately 4.7 years in the salpingectomy group and 8.5 years in the comparison group.
• Risk is reduced, not eliminated: A woman can still develop an ovarian, tubal or primary peritoneal cancer after salpingectomy.

The exact percentage will likely continue to be refined, but the overall direction of the evidence is increasingly difficult to dismiss.

Average Risk and Genetic High Risk Are Not the Same

The clearest current application is for an average-risk woman who has completed childbearing and is already undergoing an appropriate operation.

The decision is more complex for women with a pathogenic BRCA1, BRCA2 or other inherited ovarian cancer-risk variant. For these women, the established preventive operation remains risk-reducing bilateral salpingo-oophorectomy—removal of both tubes and ovaries—at an age determined by the specific mutation, family history and completion of childbearing.

Removing the tubes first and delaying ovary removal is an appealing strategy because it postpones surgical menopause. However, it has not yet been proven to provide the same cancer protection as removing the tubes and ovaries together. Trials including SOROCk are examining this question.

Women with ovarian, fallopian-tube, primary peritoneal or certain breast cancers in their personal or family history should consider formal genetic risk assessment rather than assuming they are at average risk.

What Women Should Ask Before Surgery

A woman who has completed childbearing and is planning a hysterectomy, tubal sterilization or another appropriate pelvic surgery may want to ask:

• Will my fallopian tubes be completely removed?
• Can my healthy ovaries remain in place?
• Would salpingectomy add meaningful risk or operative time in my case?
• Do my personal or family cancer histories suggest that I need genetic counseling?
• If I have a high-risk mutation, what is the evidence for removing the tubes now and the ovaries later?
• How will the removed tubes be examined by pathology?

Prevention Should Include Hormonal Consequences

This development represents preventive medicine at its best: identify where a lethal disease actually begins and intervene before it becomes clinically visible.

It also illustrates why cancer prevention and hormonal health should not be treated as unrelated subjects. Removing the fallopian tubes may substantially reduce the risk of the deadliest ovarian cancer subtype while preserving ovarian function. Removing the ovaries carries a different set of consequences that must be considered alongside cancer risk, age, genetics, bone health, cardiovascular health and the potential role of hormone therapy.

The goal is not simply to remove more tissue. It is to make a better-informed preventive decision for the individual woman.

Frequently Asked Questions

Does most ovarian cancer actually begin in the fallopian tubes?

Many high-grade serous ovarian cancers appear to begin in the fallopian tubes, particularly near their fimbrial ends. Not every ovarian cancer subtype begins there.

Does removing the fallopian tubes cause menopause?

Not intentionally. The ovaries remain in place and continue producing hormones. Current evidence has not demonstrated a meaningful short-term effect on ovarian function or the timing of menopause, although longer-term study is continuing.

How much can salpingectomy reduce ovarian cancer risk?

The 2026 British Columbia study reported approximately a 78% relative reduction in serous ovarian cancer. Other reviews have estimated reductions ranging from approximately 50% to 80%, depending on the population, procedure and cancer subtype examined.

Should every woman have her fallopian tubes removed?

No. For an average-risk woman, salpingectomy is usually considered when she has completed childbearing and is already undergoing an appropriate pelvic or abdominal surgery. A separate preventive operation may not provide enough absolute benefit to justify its surgical risks.

Is salpingectomy enough for a woman with a BRCA mutation?

It is not currently proven equivalent to removing both the tubes and ovaries. Women with BRCA1, BRCA2 or another high-risk mutation should receive individualized counseling from clinicians experienced in hereditary cancer prevention.

Can ovarian cancer still occur after the tubes are removed?

Yes. Salpingectomy reduces risk but does not eliminate cancers arising from the ovaries, residual tubal tissue or the peritoneal lining.

Editorial Transparency

This article is educational and does not provide individualized medical or surgical advice. Decisions about salpingectomy, ovarian preservation, genetic testing and hormone therapy should be based on personal risk, family history, age, reproductive plans and consultation with qualified clinicians. HormoneSynergy® receives no compensation from the authors or publishers of the research discussed.

Explore more evidence-based education in the HormoneSynergy Preventive Longevity Medicine Resource Library.